Table 2.
Clinical characteristics and oncologic and fertility outcomes of eight patients with G2EA.
| Patients | Age | Initial disease | Recurrent disease | Pregnancy | Status, Follow-up (months) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Initial diagnosis | Initial treatment | CR | Time to CR (months) | Time to recurrence (months) | Recurrent diagnosis | Repeated treatment | Response to retreatment (months) | Hysterectomy (pathology) | ||||
| 1 | 31 | G1-2 EA | MPA 500 mg/day | N | / | / | / | / | / | Y (EA, IIIC1) | / | NED (21) |
| 2 | 23 | G1-2 EA | MA 160 mg bid → GnRHa every 4 weeks + LNG-IUS | Y | 9 | Y (17) | AH2-3 | GnRHa every 4 weeks + LNG-IUS | CR (3) | N | Suggest IVF | NED (28) |
| 3 | 31 | G2 EA | MA 160 mg bid | Y | 3 | N | / | / | / | N | NFTD | NED (31) |
| 4 | 27 | G1-2 EA | MA 160 mg bid | Y | 3 | Y (24) | G2-3 EA | MA 160 mg bid | NC (4) | Y (EA, IIIC1) | / | NED (30) |
| 5 | 26 | G1-2 EA | GnRHa every 4 weeks + aromatase inhibitor + LNG-IUS | Y | 3 | N | / | / | / | N | Postpone pregnancy | NED (33) |
| 6 | 35 | G1-2 EA | MPA 500 mg/day | Y | 3 | N | / | / | / | Y (EA, IA) | / | NED (31) |
| 7 | 26 | G1 EA, focal lesions ofG2 | MA 160 mg bid | Y | 6 | Y (36) | AH3 | MA 160 mg bid | CR (6) | N | NFTD | NED (39) |
| 8 | 22 | G1-2 EA | MPA 500 mg/day | Y | 6 | N | / | / | / | N | Unmarried | NED (77) |
MPA, medroxyprogesterone acetate; MA, megestrol acetate; IVF, in-vitro fertilization; GnRHa, gonadotropin-releasing hormone agonist; LNG-IUS, levonorgestrel-intrauterine system; EA, endometrioid adenocarcinoma; AH, atypical hyperplasia; CR, complete response; NC, no change; NED, no evidence of disease; NFTD, normal full-term delivery; G, grade; Y, yes; N, no.